|
|
Les Taissounieres - 1681 Route des Dolines
, Bat HB4 France
phone:+33 (0)4 97 24 53 00
fax:+33 (0)4 97 24 53 99
|
|
| Symbol |
NCOX |
| Exchange |
EPA |
| Founded |
0 |
| Employees |
|
|
|
| www.nicox.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Using properties of nitric oxide to design and develop drugs. |
|
| Management |
| Michele GARUFI, Chairman and CEO; Maarten BEEKMAN, Vice President, Clinical Development & Medical Affairs; Eric CASTALDI, Chief Financial Officer; Jacques DJIAN, Vice President, Exploratory Development & Translational Medicine; Ennio ONGINI, Vice President, Research |
| |
|
|
|
|
|
|
|
| Keywords |
| inflammatory, cardiometabolic, ophthalmological, nitric, oxide-donating |
|
|
|
| Description |
|
NicOx is using recently-discovered properties of nitric oxide to design and develop safer and more effective drugs. NicOx creates patentable new compounds by grafting a nitric oxide-donating moiety onto existing drugs. |
|
| Products / Services |
The company currently has 7 compounds in clinical development, 5 in Phase II and 2 in Phase I.
|
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
